Precigen (I5X) Stock Price & Analysis
I5X Stock Chart & Stats
- Day’s Range
- EUR 5.72 - EUR 5.80
- 52-Week Range
- EUR 2.60 - EUR 7.68
- Previous Close
- EUR 5.46
- Volume
- N/A
- Average Volume (3M)
- 72
- Market Cap
- EUR 2.22B
- Enterprise Value
- EUR 2.42B
- Total Cash (Recent Filing)
- EUR 38.21M
- Total Debt (Recent Filing)
- EUR 98.34M
- Price to Earnings (P/E)
- ―
- Beta
- 0.77
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid PAPZIMEOS Adoption
The sharp increase in PAPZIMEOS revenue and launch-to-date sales indicates meaningful commercial traction for the company’s lead product. Continued adoption can improve operating leverage, support reinvestment in the pipeline, and establish a durable revenue base beyond collaboration-dependent income.
Reimbursement And Exclusivity Support
Broad payer coverage, clearer reimbursement through the permanent J-code, and multi-year U.S. exclusivity strengthen PAPZIMEOS’s commercial position. These protections can reduce access friction, support prescribing and reimbursement, and provide a sustained window for revenue development.
Durable Clinical Differentiation
Long-lasting complete responses provide evidence of clinically meaningful durability, which can differentiate PAPZIMEOS from alternatives and support physician confidence. A durable treatment effect may also improve patient and payer value perceptions as the product expands commercially.
Bears Say
Heavy Cash Consumption
Materially negative operating and free cash flow show that the broader business has not yet funded itself internally. Continued cash consumption could require additional financing, constrain investment choices, and expose the company to funding risk if breakeven is delayed.
Elevated Leverage
Debt substantially exceeds the company’s equity base, leaving a relatively limited cushion against operating setbacks. Interest obligations and the need to service debt can absorb cash that might otherwise support commercialization or research, increasing financial sensitivity to execution risk.
Margin And Spending Pressure
The reported quarter benefited from pre-approval inventory effects, so steady-state margins will be lower than the headline 95%. At the same time, higher commercial and expected pipeline spending may reduce operating leverage and make recent profitability harder to sustain.
Precigen News
I5X FAQ
What was Precigen’s price range in the past 12 months?
What is Precigen’s market cap?
When is Precigen’s upcoming earnings report date?
How were Precigen’s earnings last quarter?
Is Precigen overvalued?
Does Precigen pay dividends?
What is Precigen’s EPS estimate?
How many shares outstanding does Precigen have?
What happened to Precigen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Precigen?
What is the TipRanks Smart Score and how is it calculated?
Precigen Stock Smart Score
Company Description
Precigen
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Helen Sabzevari
- Employees
- 160
- Website
- www.precigen.com
- Address
- 20374 Seneca Meadows Parkway, Germantown, MD, 20876, US
Precigen (I5X) Earnings & Revenues
I5X Earnings Call
Earnings Call SentimentPositive
The call conveyed strong commercial momentum for PAPZIMEOS driven by exceptional Q2 revenue growth (>145% QoQ), launch-to-date revenue >$78M, broad payer coverage (~315M lives), durable clinical responses (83% ongoing CR >3 years), and attainment of profitability for the quarter and first half of 2026. Operational and financial risks noted include normalization of gross margins after remaining prelaunch inventory is consumed, reliance on accounts receivable collections and existing debt interest expense, rising commercial and future R&D spend, and limited public granularity on exact account activation counts and non-hub patient visibility. Overall, the positive revenue, profitability, coverage, and durability developments materially outweigh the manageable operational and financial caveats.
View all DE:I5X earnings summariesI5X Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 6 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 8 | 0 | 4 |
